Skip to main content
SpringerLink
Log in

WHO-Klassifikation von 2016 und erste S3-Leitlinie zum Nierenzellkarzinom

Was ist wichtig für die Praxis?

WHO classification 2016 and first S3 guidelines on renal cell cancer

What is important for the practice?

  • Schwerpunkt: Nierentumoren
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Die erste S3-Leitlinie Nierenzellkarzinom berücksichtigt neben praktischen Aspekten der Bildgebung, Diagnostik und Therapie auch die klinische Relevanz der Pathologiebefundung. Die S3-Leitlinie empfiehlt die Verwendung der neuen WHO-Klassifikation von 2016. Die vorliegende Übersicht fasst die Veränderungen der WHO-Klassifikationen bei der histopathologischen Diagnostik und der Befundabfassung für die Nierentumoren zusammen. Es wird eine kurze Übersicht über neue Tumorentitäten, Modifikationen der bisherigen Tumorentitäten und provisorische Tumorentitäten gegeben. Für papilläre und für klarzellige Nierenzellkarzinome wird das WHO/ISUP-Gradierungssystem benutzt, welches das bisher verwendete Fuhrman-Grading ablösen soll.

Abstract

The first S3 guidelines on renal cell cancer cover the practical aspects of imaging, diagnostics and therapy as well as the clinical relevance of pathology reporting. This review summarizes the changes in renal tumor classification and the new recommendations for reporting renal cell tumors. The S3 guidelines recommend the 2016 World Health Organization (WHO) classification of renal cell tumors. Novel renal cell tumor entities and provisional or emerging renal cell tumor entities of the 2016 WHO classification of renal tumors are discussed. The S3 guidelines for renal cell cancer also recommend the use of the WHO/International Society of Urologic Pathology (ISUP) grading system for clear cell and for papillary renal cell carcinomas, which replaces the previously used Fuhrman grading system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Amin MB, Epstein JI, Ulbright TM, Humphrey PA, Egevad L, Montironi R, Grignon D, Trpkov K, Lopez-Beltran A, Zhou M, Argani P, Delahunt B, Berney DM, Srigley JR, Tickoo SK, Reuter VE (2014) Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference. Am J Surg Pathol 38:1017–1022. doi:10.1097/PAS.0000000000000254

    Article  PubMed  Google Scholar 

  2. Amin MB, MacLennan GT, Gupta R, Grignon D, Paraf F, Vieillefond A, Paner GP, Stovsky M, Young AN, Srigley JR, Cheville JC (2009) Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol 33:384–392. doi:10.1097/PAS.0b013e3181872d3f

    Article  PubMed  Google Scholar 

  3. Argani P, Ladanyi M (2006) The evolving story of renal translocation carcinomas. Am J Clin Pathol 126:332–334. doi:10.1309/EAEJTJGD5J4J3B4F

    Article  PubMed  Google Scholar 

  4. Argani P, Lae M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE, Ladanyi M (2006) Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 24:1529–1534. doi:10.1200/JCO.2005.04.4693

    Article  CAS  PubMed  Google Scholar 

  5. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE, Ladanyi M (2005) Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 29:230–240

    Article  PubMed  Google Scholar 

  6. Azoulay S, Vieillefond A, Paraf F, Pasquier D, Cussenot O, Callard P, Sibony M (2007) Tubulocystic carcinoma of the kidney: a new entity among renal tumors. Virchows Arch 451:905–909

    Article  PubMed  Google Scholar 

  7. Berens S, Vogt P, Alkadhi H, Berger N, Moch H (2014) Thyroid-like follicular carcinoma of the kidney: a separate tumor entity? Pathologe 35:83–87. doi:10.1007/s00292-013-1772-3

    Article  CAS  PubMed  Google Scholar 

  8. Bonsib SM (2004) The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. Am J Surg Pathol 28:1594–1600

    Article  PubMed  Google Scholar 

  9. Bonsib SM (2005) T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol 174:1199–1202 (discussion 1202)

    Article  PubMed  Google Scholar 

  10. Bonsib SM (2006) Renal lymphatics, and lymphatic involvement in sinus vein invasive (pT3b) clear cell renal cell carcinoma: a study of 40 cases. Mod Pathol 19:746–753

    Article  PubMed  Google Scholar 

  11. Bonsib SM (2007) Renal veins and venous extension in clear cell renal cell carcinoma. Mod Pathol 20:44–53

    Article  PubMed  Google Scholar 

  12. Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M, Bridge JA (2011) Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 24:430–442. doi:10.1038/modpathol.2010.213

    Article  CAS  PubMed  Google Scholar 

  13. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR (2013) The international society of urological pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504. doi:10.1097/PAS.0b013e318299f0fb

    Article  PubMed  Google Scholar 

  14. Delahunt B, Eble J (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537–544

    CAS  PubMed  Google Scholar 

  15. Deml KF, Schildhaus HU, Comperat E, von Teichman A, Storz M, Schraml P, Bonventre JV, Fend F, Fleige B, Nerlich A, Gabbert HE, GaBler N, Grobholz R, Hailemariam S, Hinze R, Knuchel R, Lhermitte B, Nesi G, Rudiger T, Sauter G, Moch H (2015) Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. Am J Surg Pathol 39:889–901. doi:10.1097/PAS.0000000000000456

    Article  PubMed  Google Scholar 

  16. Doros LA, Rossi CT, Yang J, Field A, Williams GM, Messinger Y, Cajaiba MM, Perlman EJ, K AS, Cathro HP, Legallo RD, LaFortune KA, Chikwava KR, Faria P, Geller JI, Dome JS, Mullen EA, Gratias EJ, Dehner LP, Hill DA (2014) DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod Pathol 27:1267–1280. doi:10.1038/modpathol.2013.242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ficarra V, Brunelli M, Novara G, D’Elia C, Segala D, Gardiman M, Artibani W, Martignoni G (2011) Accuracy of on-bench biopsies in the evaluation of the histological subtype, grade, and necrosis of renal tumours. Pathology 43:149–155. doi:10.1097/PAT.0b013e32834317a4

    Article  PubMed  Google Scholar 

  18. Fuhrman S, Lasky L, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663

    Article  CAS  PubMed  Google Scholar 

  19. Gill AJ, Hes O, Papathomas T et al (2014) Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. doi:10.1097/PAS.0000000000000292

    Google Scholar 

  20. Grubb RL 3rd, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, Torres-Cabala C, Glenn GM, Choyke P, Merino MJ, Zbar B, Pinto PA, Srinivasan R, Coleman JA, Linehan WM (2007) Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 177:2074–2079 (discussion 2079–2080) doi:10.1016/j.juro.2007.01.155

    Article  CAS  PubMed  Google Scholar 

  21. Guo J, Tretiakova MS, Troxell ML, Osunkoya AO, Fadare O, Sangoi AR, Shen SS, Lopez-Beltran A, Mehra R, Heider A, Higgins JP, Harik LR, Leroy X, Gill AJ, Trpkov K, Campbell SC, Przybycin C, Magi-Galluzzi C, McKenney JK (2014) Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol 38:1457–1467. doi:10.1097/PAS.0000000000000248

    Article  PubMed  Google Scholar 

  22. Hakimi AA, Tickoo SK, Jacobsen A, Sarungbam J, Sfakianos JP, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB, Sankin AI, Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE (2015) TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol 28:845–853. doi:10.1038/modpathol.2015.6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H (1998) Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 153:1467–1473

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kucharczyka J, Marc R, Matranab MS, Massarid F, Scarpellie M, Cheng L, Lopez-Beltrang A, Cascinuc S, Montironie R, Moch H (2016) Emerging immunotargets in metastatic renal cell carcinoma. Curr Drug Targets

  25. Kuroda N, Ohe C, Mikami S, Inoue K, Nagashima Y, Cohen RJ, Pan CC, Michal M, Hes O (2012) Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 27:969–974

    PubMed  Google Scholar 

  26. Linehan WM, Spellman PT, Ricketts CJ et al (2015) Comprehensive molecular characterization of papillary renal-cell. Carcinoma N Engl J Med. doi:10.1056/NEJMoa1505917

    PubMed  Google Scholar 

  27. Lohse CM, Gupta S, Cheville JC (2015) Outcome prediction for patients with renal cell carcinoma. Semin Diagn Pathol 32:172–183. doi:10.1053/j.semdp.2015.02.008

    Article  PubMed  Google Scholar 

  28. Medeiros LJ, Palmedo G, Krigman HR, Kovacs G, Beckwith JB (1999) Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am J Surg Pathol 23:772–780

    Article  CAS  PubMed  Google Scholar 

  29. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM (2007) The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31:1578–1585. doi:10.1097/PAS.0b013e31804375b8

    Article  PubMed  Google Scholar 

  30. Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K, Storz M, Scherrer S, Schmid DM, Strebel RT, Probst-Hensch NM, Gerstein M, Moch H, Rubin MA (2008) Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. Int J Cancer 123:569–576

    Article  CAS  PubMed  Google Scholar 

  31. Moch H (2010) Cystic renal tumors: new entities and novel concepts. Adv Anat Pathol 17:209–214

    Article  PubMed  Google Scholar 

  32. Moch H (2014) Kidney Cancer. In: Stewart BW, Wild CP (Hrsg) World Cancer Report 2014. World Health Organization International Agency for Research on Cancer (IARC), Lyon, S 2–9

    Google Scholar 

  33. Moch H (2015) Neuroendocrine tumors of the kidneys. Pathologe 36:278–282. doi:10.1007/s00292-015-0018-y

    Article  CAS  PubMed  Google Scholar 

  34. Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T, Wild PJ (2009) Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 56:636–643

    Article  PubMed  Google Scholar 

  35. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89:604–614

    Article  CAS  PubMed  Google Scholar 

  36. Moch H, Humphrey PA, Ulbright TM, Reuter VE (2016) WHO classification of tumours of the urinary system and male genital organs. IARC, Lyon

    Google Scholar 

  37. Moch H, Montironi R, Lopez-Beltran A, Cheng L, Mischo A (2015) Oncotargets in different renal cancer subtypes. Curr Drug Targets 16:125–135

    Article  CAS  PubMed  Google Scholar 

  38. Pflueger D, Sboner A, Storz M, Roth J, Comperat E, Bruder E, Rubin MA, Schraml P, Moch H (2013) Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. Neoplasia 15:1231–1240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, Latif F, Maher ER (2008) Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100:1260–1262. doi:10.1093/jnci/djn254

    Article  CAS  PubMed  Google Scholar 

  40. Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW, Gopalan A, Reuter VE, Rosenblum MK, Russo P, Tickoo SK (2011) Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol 24:1207–1220. doi:10.1038/modpathol.2011.80

    Article  CAS  PubMed  Google Scholar 

  41. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45:860–867. doi:10.1038/ng.2699

    Article  CAS  PubMed  Google Scholar 

  42. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P (2013) The international society of urological pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489. doi:10.1097/PAS.0b013e318299f2d1

    Article  PubMed  Google Scholar 

  43. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H (2013) Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol 37:1518–1531. doi:10.1097/PAS.0b013e318299f12e

    Article  PubMed  PubMed Central  Google Scholar 

  44. Tickoo SK, Deperalta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB (2006) Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30:141–153

    Article  PubMed  Google Scholar 

  45. Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR (2013) Handling and staging of renal cell carcinoma: the international society of urological pathology consensus (ISUP) conference recommendations. Am J Surg Pathol 37:1505–1517. doi:10.1097/PAS.0b013e31829a85d0

    Article  PubMed  Google Scholar 

  46. Turbiner J, Amin MB, Humphrey PA, Srigley JR, De Leval L, Radhakrishnan A, Oliva E (2007) Cystic nephroma and mixed epithelial and stromal tumor of kidney: a detailed clinicopathologic analysis of 34 cases and proposal for renal epithelial and stromal tumor (REST) as a unifying term. Am J Surg Pathol 31:489–500

    Article  PubMed  Google Scholar 

  47. UICC (2009) TNM classification of malignant tumours. Wiley-Blackwell, Hoboken

    Google Scholar 

  48. von Teichman A, Comperat E, Behnke S, Storz M, Moch H, Schraml P (2011) VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. Lat Pathol : Off J U S Can Acad Pathol 24:571–578. doi:10.1038/modpathol.2010.222

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Universitätsspital Zürich, Schmelzbergstr.12, 8091, Zürich, Schweiz

    H. Moch

Authors
  1. H. Moch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Moch.

Ethics declarations

Interessenkonflikt

H. Moch gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Additional information

Redaktion

H.A. Baba, Essen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moch, H. WHO-Klassifikation von 2016 und erste S3-Leitlinie zum Nierenzellkarzinom. Pathologe 37, 127–133 (2016). https://doi.org/10.1007/s00292-016-0144-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-016-0144-1

Schlüsselwörter

Keywords

Search

Navigation